TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7065957

Group type: EXPERIMENTAL
Intervention: 1% epinephrine borate added three hours after 0.5% timolol maleate
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1% epinephrine borate added five minutes after 0.5% timolol maleate
Number of subjects: 14
Study: 31834114

Group type: EXPERIMENTAL
Intervention: Tube B (MiniONE)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Tube A (MIC-KEY)
Number of subjects: 158
Study: 30129806

Group type: EXPERIMENTAL
Intervention: Combination of Nigella sativa and Vitex agnus-castus with citalopram
Number of subjects: 46

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 46
Study: 28810844

Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28155305

Group type: EXPERIMENTAL
Intervention: Training programme for Tanzanian caregiver students in relational communication therapy (RCT)
Number of subjects: 12
Study: 25133996

Group type: EXPERIMENTAL
Intervention: Total body mass
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Total fat mass
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Total lean mass
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Total thigh and total abdominal fat
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Thigh fat
Number of subjects: 176
Study: 22453077

Group type: COMPARATOR
Intervention: Standard dissemination
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Facilitation model 1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Facilitation model 2
Number of subjects: 24
Study: 19118980

Group type: EXPERIMENTAL
Intervention: Anterior temporal lobe resection (ATLR)
Number of subjects: 16
Study: 17449836

Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contingencies (reward)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of medication and contingencies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of medication and reward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of medication and response cost
Number of subjects: 0
Study: 15057257

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg before intercourse
Number of subjects: 30

Group type: COMPARATOR
Intervention: CPAP during night time sleep
Number of subjects: 30
Study: 16459225

Group type: EXPERIMENTAL
Intervention: DAG meal (10 g of DAG oil)
Number of subjects: 43

Group type: COMPARATOR
Intervention: TAG meal (10 g of TAG oil)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: DAG meal
Number of subjects: 43

Group type: COMPARATOR
Intervention: TAG meal
Number of subjects: 43
Study: 10802151

Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nifedipine, 30 mg/day
Number of subjects: 24
Study: 8858389

Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra, UK‐92,480)
Number of subjects: 12
Study: 1353368

Group type: EXPERIMENTAL
Intervention: bisoprolol 10 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: diazepam 5 mg twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 40
Study: 6143631

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICI 118551 (beta 2 antagonist)
Number of subjects: 0
Study: 31573913

Group type: EXPERIMENTAL
Intervention: Appearance-based intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard information (Control)
Number of subjects: 70
Study: 30235680

Group type: EXPERIMENTAL
Intervention: Smartphone-based obesity management services for 24 weeks
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 324
Study: 27243978

Group type: EXPERIMENTAL
Intervention: Exposure session with never-used safety behaviour (NU)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Exposure session with routinely used safety behaviour (RU)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Exposure session with no safety behaviour (ERP)
Number of subjects: 57
Study: 24559858

Group type: EXPERIMENTAL
Intervention: Botox injection at the bladder neck (100 IU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard conservative treatment (both groups)
Number of subjects: 20
Study: 22172443

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 744
Study: 20620037

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 microg via Respimat inhaler once daily for 48 weeks
Number of subjects: 3991

Group type: COMPARATOR
Intervention: Placebo via Respimat inhaler once daily for 48 weeks
Number of subjects: 3991
Study: 17289892

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg, twice daily starting on day 2 of cycle 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Irinotecan (escalated doses of 180, 200, 220, and 260 mg/m2 in FOLFIRI regimen)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 15855216

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation at 400 mg/day for 9 months
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo control (no vitamin E)
Number of subjects: 400
Study: 11939671

Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (Kliogest)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9571328

Group type: EXPERIMENTAL
Intervention: High-salt diet (255 mEq of sodium daily)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-salt diet (85 mEq of sodium daily)
Number of subjects: 19
Study: 7542021

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy in addition to best supportive care
Number of subjects: 61

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 61
Study: 30239824

Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET)
Number of subjects: 1280
Study: 28532471

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 25352095

Group type: EXPERIMENTAL
Intervention: MKT alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Excimer laser alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Excimer + MKT
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (untreated patches)
Number of subjects: 39
Study: 24252934

Group type: EXPERIMENTAL
Intervention: BWSTT with power‐assisted functional electrical stimulation
Number of subjects: 30
Study: 23120952

Group type: EXPERIMENTAL
Intervention: Albendazole (study arm)
Number of subjects: 3080

Group type: COMPARATOR
Intervention: Placebo (control arm)
Number of subjects: 3080
Study: 18518863

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Galantamine (long-term treatment > 6 months)
Number of subjects: 4116

Group type: EXPERIMENTAL
Intervention: Galantamine (short-term treatment ≤ 6 months)
Number of subjects: 4116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4116
Study: 16269184

Group type: EXPERIMENTAL
Intervention: pegylated interferon α-2b (1.5 μg/kg once weekly) plus ribavirin (800 mg daily) for 48 weeks for HCV genotypes 1/4 and 24 weeks for genotypes 2/3
Number of subjects: 122
Study: 15351552

Group type: EXPERIMENTAL
Intervention: Endurance plus moderate resistance (MR) training
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Endurance plus low resistance (LR) training
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Endurance training only
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 11505346

Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional extubation
Number of subjects: 100
Study: 9006691

Group type: EXPERIMENTAL
Intervention: Reconstruction of the ligaments as described by Karlsson et al. (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modification of the Broström procedure as described by Gould et al. (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group II
Number of subjects: 60
Study: 8422279

Group type: EXPERIMENTAL
Intervention: Cisplatin or carboplatin and cyclophosphamide with or without doxorubicin for six courses after primary surgery
Number of subjects: 226
Study: 3668980

Group type: EXPERIMENTAL
Intervention: Cold provocation (cold challenges)
Number of subjects: 25
Study: 29306047

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral strategy for discontinuing long-term serotonin reuptake inhibitors (SRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced control condition
Number of subjects: 0
Study: 27169630

Group type: EXPERIMENTAL
Intervention: Brief smoking cessation (SC) advice using the AWARD model, active referral to SC services plus a referral card and a health warning leaflet (active referral group)
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: Brief SC advice using AWARD model and health warning leaflet (brief advice group)
Number of subjects: 1291

Group type: COMPARATOR
Intervention: General very brief advice with a self-help booklet (control group)
Number of subjects: 1291
Study: 24642779

Group type: EXPERIMENTAL
Intervention: Dairy dessert containing maltitol and scFOS (35g dosage)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control dessert containing dextrose
Number of subjects: 36
Study: 23084678

Group type: EXPERIMENTAL
Intervention: 4-point, full-sized mesh method
Number of subjects: 87

Group type: COMPARATOR
Intervention: 2-point, half-sized mesh method
Number of subjects: 87
Study: 21073697

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1334
Study: 18720469

Group type: EXPERIMENTAL
Intervention: Transverse coloplasty pouch (TCP)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Colon J pouch (CJP)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Both groups (TCP and CJP)
Number of subjects: 149
Study: 16012278

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) + Cognitive Behavioral Therapy (12 sessions)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) + Motivational Enhancement Therapy (4 sessions)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy (12 sessions)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo + Motivational Enhancement Therapy (4 sessions)
Number of subjects: 160
Study: 14964345

Group type: EXPERIMENTAL
Intervention: Lacteol group (2 capsules of Lacteol Fort twice a day for 4 weeks)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Lacidophilin group (5 chewable tablets of Lacidophilin three times a day for 4 weeks)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Lacteol group
Number of subjects: 137
Study: 10568184

Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (27 grafts in phase 1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (86 grafts in phase 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (17 untreated grafts in phase 1)
Number of subjects: 100
Study: 8759812

Group type: EXPERIMENTAL
Intervention: zofenopril (7.5 to 30 mg twice daily)
Number of subjects: 1146

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1146
Study: 1816661

Group type: EXPERIMENTAL
Intervention: Dried unripe fruit powder of 'bel' (Aegle marmelos)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dried powdered plant of 'thankuni' (Hydrocotyle asiatica)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dried powdered plant of 'gandhavadulia' (Paederia foetida)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 7065839

Group type: EXPERIMENTAL
Intervention: 20 mg of dextroamphetamine (intravenous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-blind pimozide treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prepimozide psychosis ratings
Number of subjects: 0
Study: 31358046

Group type: EXPERIMENTAL
Intervention: Micro-fragmented adipose tissue injection (Lipogems®)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 114
Study: 29912357

Group type: EXPERIMENTAL
Intervention: Biocarbon at 0.5% of substrate DM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Biocarbon at 1% of substrate DM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Biocarbon at 2% of substrate DM
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (0% biocarbon)
Number of subjects: 16
Study: 27176822

Group type: EXPERIMENTAL
Intervention: Tdap vaccine during pregnancy
Number of subjects: 346
Study: 24798113

Group type: EXPERIMENTAL
Intervention: Diclofenac suppository
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Indomethacin suppository
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22469659

Group type: EXPERIMENTAL
Intervention: Web-based education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face education
Number of subjects: 0
Study: 19744462

Group type: EXPERIMENTAL
Intervention: Right hemihepatectomy preserving ventral RAS
Number of subjects: 30
Study: 17283264

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Top third CRP levels
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Adjusted CRP levels
Number of subjects: 5804

Group type: EXPERIMENTAL
Intervention: Baseline CRP
Number of subjects: 5804
Study: 15197541

Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg daily
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Ibandronate 20 mg intermittently
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Ibandronate 1.0 mg IV every 3 months
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Ibandronate 0.5 mg IV every 3 months
Number of subjects: 474

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study: 11892374

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 34000

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 34000
Study: 9841833

Group type: EXPERIMENTAL
Intervention: Ia-TT conjugate (dose range, 3.75-63 microg of CPS component)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Ib-TT conjugate (dose range, 3.75-63 microg of CPS component)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Uncoupled Ia CPS
Number of subjects: 190

Group type: COMPARATOR
Intervention: Uncoupled Ib CPS
Number of subjects: 190

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 190
Study: 8749599

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinylestradiol and levonorgestrel
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive containing ethinylestradiol and desogestrel
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 2031076

Group type: EXPERIMENTAL
Intervention: 125 micrograms of cyclopenthiazide
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 500 micrograms of cyclopenthiazide
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (during 8-week run-in period)
Number of subjects: 73
Study: 6124805

Group type: EXPERIMENTAL
Intervention: Early phototherapy started at serum bilirubin 250 mumol/l
Number of subjects: 40

Group type: COMPARATOR
Intervention: Late phototherapy started at serum bilirubin 320 mumol/l
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 40
Study: 29736552

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left inferior frontal gyrus (l-IFG)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left posterior superior temporal gyrus (l-STG)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham-tDCS/pseudo-stimulation
Number of subjects: 13
Study: 27419128

Group type: EXPERIMENTAL
Intervention: Er:YAG laser with Clearfil s3 Bond Plus
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Er:YAG laser with Xeno® Select
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Er:YAG laser with Futurabond U
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diamond bur with Clearfil s3 Bond Plus
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diamond bur with Xeno® Select
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Diamond bur with Futurabond U
Number of subjects: 72

Group type: COMPARATOR
Intervention: Comparison of enamel with cervical walls
Number of subjects: 72
Study: 25617202

Group type: EXPERIMENTAL
Intervention: Self-collection of HPV DNA offered by community health workers during home visits
Number of subjects: 7650

Group type: COMPARATOR
Intervention: Standard advice to attend a health clinic for cervical screening
Number of subjects: 7650
Study: 23696855

Group type: EXPERIMENTAL
Intervention: Serum beta-hCG levels on day 7 after medical abortion
Number of subjects: 2843

Group type: EXPERIMENTAL
Intervention: Serum beta-hCG levels on day 14 after medical abortion
Number of subjects: 2843

Group type: EXPERIMENTAL
Intervention: Serum Ang-2 levels on day 7 after medical abortion
Number of subjects: 2843

Group type: EXPERIMENTAL
Intervention: Serum Ang-2 levels on day 14 after medical abortion
Number of subjects: 2843

Group type: EXPERIMENTAL
Intervention: Correlation between Ang-2 and beta-hCG levels
Number of subjects: 2843
Study: 20578849

Group type: EXPERIMENTAL
Intervention: Immediate orthodontic loading (11 implants)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (9 implants)
Number of subjects: 13
Study: 18197267

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 203
Study: 16798470

Group type: EXPERIMENTAL
Intervention: (99m)Tc‐DTPA aerosol scintigraphy
Number of subjects: 25

Group type: COMPARATOR
Intervention: DLCO
Number of subjects: 25
Study: 12702108

Group type: EXPERIMENTAL
Intervention: Er:YAG laser + SRP (test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Er:YAG laser alone (control)
Number of subjects: 20
Study: 10994565

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 500

Group type: COMPARATOR
Intervention: Teicoplanin (surgical room)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Vancomycin (surgical room)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Teicoplanin (medical ward)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Vancomycin (medical ward)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Teicoplanin (VR patients, surgical room)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Vancomycin (VR patients, surgical room)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Teicoplanin (VR patients, medical ward)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Vancomycin (VR patients, medical ward)
Number of subjects: 500
Study: 9078827

Group type: EXPERIMENTAL
Intervention: Survanta (n = 15)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Exosurf (n = 12)
Number of subjects: 27
Study: 7943919

Group type: EXPERIMENTAL
Intervention: Articaine hydrochloride with 1:200,000 epinephrine (Ultracain DS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine with 1:80,000 epinephrine (Xylocain‐Adrenalin)
Number of subjects: 20
Study: 3082677

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin vasodilator cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29314645

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo→tofacitinib 5 mg twice daily
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo→tofacitinib 10 mg twice daily
Number of subjects: 216
Study: 27340919

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2933

Group type: COMPARATOR
Intervention: Vasodilators and diuretics
Number of subjects: 2933
Study: 23792149

Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg loading dose followed by 40 mg every 2 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 23064592

Group type: EXPERIMENTAL
Intervention: model-based magnetization transfer (mMT) imaging
Number of subjects: 54

Group type: COMPARATOR
Intervention: magnetization transfer ratio (MTR)
Number of subjects: 54
Study: 20629134

Group type: EXPERIMENTAL
Intervention: Exercise program (6-month minimally supervised); attended a monthly exercise class and exercised at home three times weekly
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 18373988

Group type: EXPERIMENTAL
Intervention: MP+SS (massed practice training combined with somatosensory stimulation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SS (somatosensory stimulation only)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MP (massed practice training only)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 24
Study: 16093518

Group type: EXPERIMENTAL
Intervention: Posttraumatic growth (PTG) reported by adolescents and their parents
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Perceived treatment severity and life threat
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Posttraumatic stress symptoms (PTSS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Diagnosis after age 5
Number of subjects: 150
Study: 12658206

Group type: EXPERIMENTAL
Intervention: Active amiodarone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Discontinued amiodarone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amiodarone (both active and discontinued)
Number of subjects: 82
Study: 10678690

Group type: EXPERIMENTAL
Intervention: Invariable, neutral distractors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Variable, task-relevant distractors
Number of subjects: 0
Study: 8777336

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg b.i.d. for 3 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg b.i.d. for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pretreatment period (no intervention)
Number of subjects: 0